Stephens Investment Management Group LLC Buys 37,057 Shares of Repligen Co. (NASDAQ:RGEN)

Stephens Investment Management Group LLC grew its position in Repligen Co. (NASDAQ:RGEN - Free Report) by 7.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 536,801 shares of the biotechnology company's stock after purchasing an additional 37,057 shares during the period. Repligen comprises about 1.0% of Stephens Investment Management Group LLC's portfolio, making the stock its 28th largest position. Stephens Investment Management Group LLC owned about 0.96% of Repligen worth $77,267,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in the company. UMB Bank n.a. raised its position in Repligen by 49.1% in the fourth quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company's stock worth $48,000 after acquiring an additional 110 shares during the period. First Turn Management LLC bought a new position in Repligen during the third quarter worth about $13,202,000. Thrivent Financial for Lutherans increased its stake in shares of Repligen by 6.1% in the third quarter. Thrivent Financial for Lutherans now owns 638,602 shares of the biotechnology company's stock worth $95,037,000 after purchasing an additional 36,773 shares in the last quarter. Geneva Capital Management LLC raised its position in shares of Repligen by 8.5% in the third quarter. Geneva Capital Management LLC now owns 138,677 shares of the biotechnology company's stock valued at $20,638,000 after purchasing an additional 10,908 shares during the period. Finally, TimesSquare Capital Management LLC lifted its stake in shares of Repligen by 14.6% during the 3rd quarter. TimesSquare Capital Management LLC now owns 275,627 shares of the biotechnology company's stock valued at $41,019,000 after buying an additional 35,115 shares in the last quarter. 97.64% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on RGEN shares. Canaccord Genuity Group assumed coverage on Repligen in a report on Tuesday, December 17th. They set a "hold" rating and a $165.00 target price for the company. HC Wainwright decreased their price target on shares of Repligen from $240.00 to $180.00 and set a "buy" rating on the stock in a report on Thursday, January 23rd. Wolfe Research initiated coverage on Repligen in a research note on Thursday, November 14th. They set a "peer perform" rating for the company. StockNews.com upgraded Repligen from a "sell" rating to a "hold" rating in a research note on Friday, January 3rd. Finally, Canaccord Genuity Group began coverage on Repligen in a research report on Tuesday, December 17th. They set a "hold" rating and a $165.00 price target for the company. Six investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $186.00.

Repligen Trading Down 2.5 %

Shares of RGEN traded down $3.77 during mid-day trading on Wednesday, reaching $145.72. The company's stock had a trading volume of 739,493 shares, compared to its average volume of 553,964. Repligen Co. has a 52 week low of $113.50 and a 52 week high of $211.13. The stock has a market cap of $8.16 billion, a PE ratio of -393.83, a P/E/G ratio of 4.54 and a beta of 0.99. The company's fifty day moving average price is $155.45 and its two-hundred day moving average price is $149.14. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, topping the consensus estimate of $0.34 by $0.09. The business had revenue of $154.87 million during the quarter, compared to the consensus estimate of $153.34 million. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. During the same period in the previous year, the firm posted $0.23 earnings per share. The firm's revenue for the quarter was up 9.7% on a year-over-year basis. On average, analysts predict that Repligen Co. will post 1.54 earnings per share for the current fiscal year.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.